Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Braz. j. oral sci ; 21: e227017, jan.-dez. 2022. ilus
Article in English | LILACS, BBO | ID: biblio-1393192

ABSTRACT

During COVID-19 pandemic, fulminant deep fungal infection started emerging in India, known as Mucormycosis. This type of mucormycosis was termed as COVID-19 associated mucormycosis (CAM). These patients had previous history of COVID-19 infection. Such cases were mainly reported in immunocompromised patients such as patients with poorly controlled diabetes and chronic renal diseases etc. Rhinomaxillary mucormycosis is an aggressive, fulminant, fatal deep fungal infection of head and neck region. Early diagnosis and prompt treatment can reduce the mortality and morbidity associated with the disease; hence we present case series of rhinomaxillary mucormycosis to create awareness amongst dental surgeons


Subject(s)
Humans , Male , Middle Aged , Aged , Signs and Symptoms , Comorbidity , Invasive Fungal Infections/diagnosis , COVID-19 , Mucorales , Mucormycosis/epidemiology , Mycoses/diagnosis
2.
Rev. Asoc. Odontol. Argent ; 110(2): 1100851, may.-ago. 2022.
Article in Spanish | LILACS | ID: biblio-1419080

ABSTRACT

La mucormicosis es una infección fúngica rara, con alta morbilidad y mortalidad. Se presenta principalmente en pa- cientes con diabetes mellitus no controlada, inmunocompro- metidos, con tratamiento crónicos con esteroides, entre otros. Actualmente, se cree que la pandemia de COVID-19 y los tratamientos con corticosteroides podrían estar implicados en el aumento de casos de esta micosis. Este hongo invade el sistema vascular, ocluyendo el flujo sanguíneo arterial y generando una rápida trombosis e isque- mia, lo que provoca la necrosis de los tejidos duros y blandos, con invasión rápida a los tejidos circundantes. Hay varias formas clínicas. En la cavidad bucal se presenta la variante rino-orbito-cerebral, que afecta el paladar en forma de lesión eritematosa o grisácea que puede progresar hacia la formación de una masa necrótica o ulceración con muy escaso sangrado de mucosa. Se manifiesta con síntomas típicos de una rinosinusitis con fiebre y dolor en las piezas dentarias superiores. El tratamiento consta de tres pilares fundamentales: el diagnóstico, un manejo adecuado de las comorbilidades y la combinación de las terapias antifúngica y quirúrgica. Desde el año 2020, la mucormicosis asociada a COVID-19 pasó a ser un evento de notificación obligatoria inmediata al Sistema Nacional de Vigilancia de la Salud (SNVS2.0) me- diante el Sistema Integrado de Información Sanitaria Argen- tina (SISA). Es importante destacar que se han reportado casos de mu- cormicosis luego de extracciones dentales; lo que impulsa a afianzar los conocimientos sobre esta enfermedad, extremar las medidas preventivas e incentivar el diagnóstico precoz en la atención odontológica, debido a la rapidez en la evolución de la patología (AU))


Mucormycosis is a rare fungal infection, with high mor- bidity and mortality. It occurs mainly in patients with uncon- trolled diabetes mellitus, immunocompromised, on chronic treatment with steroids, among others. Currently, it is believed that the COVID-19 pandemic and the corticosteroid treatments could be one of the causes of increased cases. This fungus invades the vascular system, occluding arteri- al blood flow and generating rapid thrombosis and ischemia, which causes necrosis of hard and soft tissues, with rapid in- vasion to the surrounding tissues. There are several clinical forms. In the oral cavity, the rhino-orbito-cerebral variant presents itself affecting the pal- ate in the form of an erythematous or grayish lesion that can progress towards the formation of a necrotic mass or ulcera- tion with very little mucosal bleeding. It manifests itself with typical symptoms of rhinosinusitis, with fever and pain in the upper teeth. The treatment consists of three fundamental pillars: diag- nosis, proper management of comorbidities and the combina- tion of antifungal and surgical therapies. Since 2020, COVID-19 associated mucormycosis became an event of mandatory immediate notification to the National Health Surveillance System (SNVS2.0,) through the Argentina Integrated Health Information System (SISA). It is important to emphasize that mucormycosis cases had been reported following tooth extractions, which drives to strengthen knowledge about this disease, extreme preventive measures and encourage early diagnosis in dental care, due to the speed of the evolution of the pathology (AU))


Subject(s)
Humans , Bacterial Infections/classification , COVID-19/complications , Mucormycosis/etiology , Argentina/epidemiology , Prognosis , Signs and Symptoms , Comorbidity , Causality , Dental Care for Chronically Ill/methods , Early Diagnosis , Diabetes Mellitus/pathology , Diagnosis, Differential , Mucormycosis/pathology , Mucormycosis/prevention & control , Mucormycosis/drug therapy , Mucormycosis/epidemiology , Antifungal Agents/therapeutic use
3.
An. bras. dermatol ; 96(2): 196-199, Mar.-Apr. 2021. tab, graf
Article in English | LILACS | ID: biblio-1248739

ABSTRACT

Abstract The authors present seven cases of rhinocerebral mucormycosis associated to diabetes mellitus, which is a disease with epidemic proportions affecting individuals worldwide, particularly in developing countries, and which poses significant morbidity and mortality. Mucormycosis is an opportunistic fungal infection with high mortality and requires an invasive therapeutic approach to save the patient's life with significant morbidity and sequelae, thus prevention is crucial.


Subject(s)
Humans , Opportunistic Infections/epidemiology , Diabetes Mellitus/epidemiology , Epidemics , Mucormycosis/diagnosis , Mucormycosis/epidemiology
4.
Braz. j. infect. dis ; 25(3): 101597, 2021. graf
Article in English | LILACS | ID: biblio-1339427

ABSTRACT

ABSTRACT Mucormycosis or black fungus infection is a less common disease but highly fatal infection, infecting the immunocompromised individuals. The site of predilection of the fungus is found to be lungs and brain in addition to its sequestration in sinusoidal spaces. Presently with the ongoing COVID 19 pandemic, the prevalence of this infection is found to be high in the Indian population. The fungus establishes itself by affecting the compromised immune system of an individual and thereby making the individual susceptible to other diseases/ infection. The reasons attributed to the sudden upsurge are steroidal therapeutics abuse, tocilizumab therapy and diabetes mellitus.To avert the cytokine storm, the medical health workers are necessitated to include steroid drugs in COVID 19 treatment protocol however inclusion of these drugs in patients who do essentially require steroids can have their immune system debilitated and permit the invasion of this fungus. According to International Diabetes Federation (IDF), 77 million Indians are known to be diabetic, cautioning the physicians to be vigilante of the impending black fungus infection in the event of COVID19 affliction in such individuals. There is causal relationship between anti-hyperglycemic drugs and weakened immune system and opportunity for the fungus invasion. This review attempts to explain the inter-relatedness of COVID19 infection, its treatment and eventual black fungus infection risk.


Subject(s)
Humans , SARS-CoV-2 , COVID-19/drug therapy , Mucormycosis/epidemiology , India/epidemiology
6.
Artrosc. (B. Aires) ; 25(3): 92-99, 2018. ilus, tab
Article in Spanish | LILACS, BINACIS | ID: biblio-972518

ABSTRACT

OBJETIVO: Describir la investigación epidemiológica de osteomielitis por Mucorales (OMM) post reparación artroscópica de LCA (RA-LCA) en Argentina. MATERIAL Y MÉTODO: 1) Revisión de los casos; 2) Relevamiento de 3 instituciones; 3) Cultivo micológico de materiales quirúrgicos; 4) Encuesta a instrumentadoras; 5) Secuenciación de las cepas de Rhizopus y 6) Redacción de recomendaciones. RESULTADOS: Del 2005 al 2017 se identificaron 40 casos de OMM (Rhizopus sp.) post reparación artroscópica de LCA en pacientes inmunocompetentes de 12 jurisdicciones de Argentina. El diagnóstico fue por cultivo (22/31), y por anatomía patológica (9). La edad promedio fue 29 años. El 84% de 38 casos eran varones. Intervinieron 13 ortopedias. El implante fue importado en 8/20 casos y nacional en 12. En las 3 instituciones se observó: manejo inadecuado del aire de quirófano, variabilidad en la limpieza del artroscopio, en el taladro utilizado, y en el manejo de materiales que llegan de las ortopedias y falta de trazabilidad de los implantes. Los cultivos micológicos de los materiales fueron negativos. La encuesta a instrumentadores confirmó los hallazgos de los relevamientos. La secuenciación de las cepas de Rhizopus demostró predominio de policlonalidad. CONCLUSIÓN: La OMM es una complicación posible luego de la RA-LCA en instituciones privadas de Argentina. No se identificó un origen único. Se detectaron múltiples prácticas que favorecen la contaminación de la cirugía con hongos filamentosos (manejo del aire de quirófano, del artroscopio, de los materiales provenientes de ortopedia, etc.). En base a estos hallazgos la Asociación Argentina de Artroscopía sugiere medidas de prevención. Implicancia clínica: Prevención de osteomielitis por Mucorales post- cirugía artroscópica para ligamento cruzado anterior. Tipo de estudio: Serie de casos. Nivel de Evidencia: IV.


OBJECTIVE: To describe the epidemiological investigation of Mucor osteomyelitis (MO) after arthroscopic repair of ACL (ARACL) in Argentina. MATERIAL Y METHODS: 1) Review of cases; 2) Survey of 3 institutions; 3) Mycological culture of surgical materials; 4) Survey of instrumentists; 5) Sequencing of Rhizopus strains and 6) Writing of recommendations. RESULTS: From 2005 to 2017, 40 cases of MO (Rhizopus sp.) Post AR-ACL were identified in immunocompetent patients from 12 jurisdictions of Argentina. The diagnosis was made by culture (22/31), and by pathology (9). The average age was 29 years. 84% of 38 cases were male. Thirteen orthopedics intervened. The implant was imported in 8/20 cases and national in 12. In the 3 institutions it was observed: inadequate handling of the operating room air, variability in the cleaning of the arthroscope, in the drill used, and in the handling of materials that come from the orthopedics and lack of traceability of the implants. The mycological cultures of the materials were negative. The survey of instrumentists confirmed the findings of the surveys. The sequencing of Rhizopus strains showed a predominance of polyclonality. CONCLUSION: MO is a possible complication after AR-ACL in private institutions in Argentina. A unique origin was not identified. Multiple practices that favor the contamination of surgery with filamentous fungi (handling of operating room air, arthroscope, materials from orthopedics, etc.) were detected. Based on these findings, the Argentine Association of Arthroscopy suggests prevention measures. Clinical relevance: Prevention of Mucor osteomyelitis after arthroscopic surgery for anterior cruciate ligament. Type study: Cases series. Level of evidence: IV.


Subject(s)
Adult , Anterior Cruciate Ligament Reconstruction/adverse effects , Arthroscopy/adverse effects , Cross Infection/epidemiology , Cross Infection/prevention & control , Mucormycosis/epidemiology , Mucormycosis/prevention & control , Mycoses/epidemiology , Mycoses/prevention & control , Osteomyelitis/epidemiology , Argentina , Risk Factors
7.
An. bras. dermatol ; 92(3): 304-311, May-June 2017. tab, graf
Article in English | LILACS | ID: biblio-886949

ABSTRACT

Abstract Cutaneous mucormycosis is an emerging fungal infection caused by opportunistic fungi of the phylum Glomeromycota. It is frequent in poorly controlled diabetic patients and individuals with immunosuppression. It is usually acquired by direct inoculation through trauma. The clinical presentation is nonspecific, but an indurated plaque that rapidly evolves to necrosis is a common finding. Diagnosis should be confirmed by demonstration of the etiological agent and new molecular diagnostic tools have recently been described. It is an invasive life-threatening disease and in order to improve survival, a prompt diagnosis and multidisciplinary management should be provided. The treatment of choice is amphotericin B, but new azoles, such as posaconazole and isavuconazole, must be considered.


Subject(s)
Humans , Dermatomycoses , Mucormycosis , Dermatomycoses/diagnosis , Dermatomycoses/microbiology , Dermatomycoses/drug therapy , Dermatomycoses/epidemiology , Mucormycosis/diagnosis , Mucormycosis/microbiology , Mucormycosis/drug therapy , Mucormycosis/epidemiology , Antifungal Agents/therapeutic use
8.
Bol. micol. (Valparaiso En linea) ; 28(1): 16-25, jun. 2013. ilus
Article in Spanish | LILACS | ID: lil-684294

ABSTRACT

El subphylum Mucoromycotina es un grupo de hongos ubicuos, saprobios, caracterizados por la presencia de hifas cenocíticas. También se caracterizan por presentar una fase sexual con la formación de una zigospora. Los mucormycetes son capaces de infectar plantas, animales y seres humanos. Recientemente, varios estudios han comunicado de la creciente incidencia de mucormicosis en pacientes inmunocomprometidos e inmunocompetentes. Dados los avances en biología molecular, la sistemática de este grupo de hongos ha experimentado varios cambios taxonómicos en los últimos años. Este artículo discutirá los principales cambios taxonómicos, en especial de los géneros y especies de interés clínico.


The subphylum Mucoromycotina is a group of fungi with several ubiquitous, and saprotrophic species which are characterized by the presence of coenocytic hyphae. Also have a sexual phase characterized by the formation of zygospores. The mucormycetes are able to infect plants, animals and humans. Recently, several studies have reported the increasing incidence of mucormycosis in both immunocompromised and immunocompetent patients. Given the advances in molecular biology, the systematic of this group of fungi has experimented several taxonomical changes. This paper will discuss the major taxonomic changes, particularly of those genera and species of clinical interest.


Subject(s)
Aerosols , Fungi , Mycoses , Mucorales/classification , Mucorales/pathogenicity , Mucormycosis/epidemiology , Mucormycosis/etiology
9.
Medicina (B.Aires) ; 72(1): 23-27, feb. 2012. ilus, tab
Article in Spanish | LILACS | ID: lil-639647

ABSTRACT

El objetivo de este trabajo es presentar la incidencia, frecuencia, características clínicas y evolución de los pacientes con mucormicosis atendidos en el Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, entre los años 1982 y 2010. Durante ese período se diagnosticaron 10 casos de mucormicosis. Los tres primeros entre 1982 y 2004 y los últimos 7 entre 2005 y 2010. La incidencia y frecuencia de esta enfermedad, para el período 1980-2004 fue 0.13 pacientes/año y 0.1 casos/10 000 egresos (IC 95%: 0.00 a 0.3) respectivamente. En el período 2005-2010 la incidencia fue 0.86 pacientes/año y la frecuencia de 1.1 casos/10 000 egresos (IC 95%: 0.5 a 2.4). Hubo nueve casos de mucormicosis rinosinuso-orbitaria, siete en pacientes con diabetes mellitus, uno en una paciente con una hemopatía maligna y neutropenia, y el restante en un paciente con HIV/sida que además estaba neutropénico y con un síndrome hemofagocítico. En una paciente se realizó el diagnóstico post mortem de mucormicosis pulmonar. El diagnóstico se efectuó por la observación de filamentos cenocíticos en los diez casos. Hubo desarrollo de mucorales en los cultivos de 8/9 pacientes; cinco Rhizopus spp y tres Mucor spp. Todos los pacientes recibieron un tratamiento inicial con anfotericina B deoxicolato, que en tres de ellos fue continuado con anfotericina B liposomal, y cirugía. Tres enfermos recibieron además un tratamiento adyuvante con oxigeno hiperbárico. La mortalidad fue 30%.


Mucormycosis is an opportunistic infection caused by fungi of the order Mucorales. It is characterized by rapid progression and high morbidity and mortality in the absence of early diagnosis and prompt treatment. It was an infrequent disease, but in recent years, its incidence appears to have increased. The aim of this paper is to report the cases of mucormycosis diagnosed from 1982 to 2010 at the Hospital de Clinicas José de San Martín, University of Buenos Aires. We diagnosed 10 cases of mucormycosis; the first three between 1982 and 2004 and the last 7 between 2005 and 2010. The incidence from 1980 to 2004 was 0.13 patient-years and the frequency 0.1/10 000 discharges (95% CI 0.00- 0.3). In the period 2005 to 2010, the incidence was 0.86 patients per year with 1.1/10 000 discharges (95% CI 0.5-2.4). There was a pulmonary mucormycosis case (in a patient treated with corticosteroids) and nine rhinocerebral cases, two in neutropenic and seven in diabetic patients. The diagnosis was made by observation of cenocytic hyphae in 10/10 patients. Mucorales were recovered in 8/9 cultures (5 Rhizopus spp and 3 Mucor spp.). In one case diagnosis of pulmonary mucormycosis was made post-mortem. Nine patients were treated with amphotericin B deoxycholate (in 3 patients supplemented with liposomal amphotericin B) and surgery. Three patients underwent hyperbaric chamber. Seven patients had favorable outcome. In conclusion, mucormycosis is a rare disease, but its incidence has increased over the past five years. A good evolution of the patients is linked to early diagnosis and treatment.


Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Mucormycosis/epidemiology , Nose Diseases/epidemiology , Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Argentina/epidemiology , Drug Combinations , Deoxycholic Acid/therapeutic use , Eye Infections, Fungal/drug therapy , Eye Infections, Fungal/epidemiology , Eye Infections, Fungal/microbiology , Incidence , Lung Diseases, Fungal/drug therapy , Lung Diseases, Fungal/epidemiology , Lung Diseases, Fungal/pathology , Mucormycosis/drug therapy , Mucormycosis/pathology , Nose Diseases/drug therapy , Nose Diseases/microbiology , Paranasal Sinus Diseases/drug therapy , Paranasal Sinus Diseases/epidemiology , Paranasal Sinus Diseases/microbiology
10.
Rev. Hosp. Clin. Univ. Chile ; 16(3): 198-203, 2005. tab, ilus
Article in Spanish | LILACS | ID: lil-531909

ABSTRACT

Revisamos los hallazgos clínicos, patológicos y tratamiento en 12 pacientes con mucormicosis en el Hospital Clínico de la Universidad de Chile entre los años 1990 y 2004. Del total de pacientes estudiados, 7 eran hombres y 5 mujeres. La edad promedio fue de 54 años, con un rango de 29 a 79 años. El diagnóstico de mucormicosisse realizó por biopsia en 10 pacientes y por estudio directo en 2 pacientes. Los factores predisponentes presentes en los pacientes estudiados fueron, diabetes mellitus, HIV en etapa SIDA y enfermedades hematológicas en tratamiento oncológico. La histología demostró necrosis e infarto con invasión de vasos sanguíneos y trombosis micótica. Todos los pacientes estudiados recibieron tratamiento con Anfotericina B y 6 fueron intervenidos quirúrgicamente. Del total de 12 pacientes, 4 fallecieron (33 por ciento) y 8 permanecen vivos (66 por ciento).


We made a review of the clinical and pathological findings and the treatment in 12 patients presenting mucormycosis in the Clinical Hospital of the University of Chile between 1990 and 2004. Of the whole studied patients, 7 were men and 5 women. The average age was 54 years, with a range from 29 to 79 years. The diagnosis of mucormycosis was performed by biopsy in 10 patients andby direct study in 2 patients. The predisposing factors in the studied patients were: Diabetes Mellitus, HIV at AIDS stage and hematological diseases in oncologic treatment. The histology demonstrated necrosis and infarction with blood vessels invasion and mycotic thrombosis. All the studied patientsreceived treatment with Anphotericine B and 6 required surgical intervention. Of the total of 12 patients, 4 died (33 percent) and 8 remain alive (66 percent).


Subject(s)
Humans , Male , Adult , Female , Middle Aged , Mucormycosis/diagnosis , Mucormycosis/epidemiology , Mucormycosis/therapy , Zygomycosis/diagnosis , Zygomycosis/epidemiology , Zygomycosis/therapy , Comorbidity , Chile/epidemiology , /epidemiology , HIV Infections/epidemiology
11.
An. otorrinolaringol. mex ; 44(3): 167-72, jun.-ago. 1999. ilus
Article in Spanish | LILACS | ID: lil-276932

ABSTRACT

Introducción. Las micosis de senos paranasales se han clasificado en invasiva y no invasiva; el tipo de micosis y su comportamiento clínico depende de la interacción entre la competencia inmunológica del paciente y la patogenicidad del microorganismo, en un determinado micro ambiente. Material y Métodos. Se realizó un estudio clínico prospectivo para evaluar las características de pacientes con sinusitis micótica. Se presentan todos los pacientes diagnosticados y tratados como sinusitis micótica en el periodo de 1994-1997. Resultados. Se encontraron 10 pacientes que correspondieron al 6 por ciento de los casos de sinusitis crónica tratados quirúrgicamente; Todos los pacientes con mucormicosis aguda invasiva recibieron tratamiento medico con anfotericina B, Insulina y refección quirúrgica con debridación extensa del tejido necrótico, resultando en control de la enfermedad subyacente y sobrevida del 50 por ciento de los pacientes. Conclusión. Es necesario diagnosticar precozmente, y dar tratamiento multi disciplinario médico y quirúrgico para lograr una mejor supervivencia de los pacientes


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aspergillosis/diagnosis , Mucormycosis/epidemiology , Mucormycosis/pathology , Mycoses/epidemiology , Mycoses/pathology , Sinusitis/etiology , Paranasal Sinuses/microbiology , Paranasal Sinuses/pathology
12.
An. bras. dermatol ; 73(2): 129-32, mar.-abr. 1998. ilus
Article in Portuguese | LILACS | ID: lil-242357

ABSTRACT

Os autores registram caso de zigomicose subcutânea em paciente do sexo feminino, com dois anos de idade, branca, natural de Porto Franco, Estado do Maranhäo - Brasil, provocada por Basidiobolus haptosporus. Os exames histopatológicos e micológicos confirmaram o diagnóstico. Em face da experiência adquirida com o tratamento desses doentes, indicam o iodeto de potássio como a droga de escolha para o tratamento dessa micose


Subject(s)
Humans , Female , Infant , Administration, Oral , Face/pathology , Potassium Iodide/therapeutic use , Mucorales/isolation & purification , Mucormycosis/drug therapy , Mucormycosis/epidemiology , Skin Tests
SELECTION OF CITATIONS
SEARCH DETAIL